EGFR and non-small cell lung carcinoma: Our data demonstrate that combinatorial treatment of the NSCLC cell lines with METF and SAL leads to a pronounced “unspecific” inhibition of EGFR, HER2, HER3 and the downstream regulators AKT and ERK1/2 expression and phosphorylation, via yet unknown mechanisms, irrespective of the mutational status and protein expression.